The mixed Q1 earnings report indicates that while some aspects of Revance Therapeutics' financial performance may have met or exceeded expectations, others fell short. This discrepancy often leads to uncertainty among investors, causing a negative short-term impact on the stock price. Given that the news directly pertains to the company's financial health, it is highly relevant and important to investors. The confidence in this analysis is high due to the direct correlation between earnings reports and stock price movements.